KR950010893A - 자궁내막증 억제 방법 - Google Patents
자궁내막증 억제 방법 Download PDFInfo
- Publication number
- KR950010893A KR950010893A KR1019940026164A KR19940026164A KR950010893A KR 950010893 A KR950010893 A KR 950010893A KR 1019940026164 A KR1019940026164 A KR 1019940026164A KR 19940026164 A KR19940026164 A KR 19940026164A KR 950010893 A KR950010893 A KR 950010893A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- endometriosis
- pyrrolidino
- piperidino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/138,643 US5461065A (en) | 1993-10-15 | 1993-10-15 | Methods for inhibiting endometriosis |
| US8/138,643 | 1993-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950010893A true KR950010893A (ko) | 1995-05-15 |
Family
ID=22482966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940026164A Ceased KR950010893A (ko) | 1993-10-15 | 1994-10-13 | 자궁내막증 억제 방법 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US5461065A (https=) |
| EP (1) | EP0652005B1 (https=) |
| JP (1) | JPH07188014A (https=) |
| KR (1) | KR950010893A (https=) |
| CN (1) | CN1049335C (https=) |
| AT (1) | ATE203404T1 (https=) |
| AU (1) | AU677700B2 (https=) |
| CA (1) | CA2118092A1 (https=) |
| CZ (1) | CZ287246B6 (https=) |
| DE (1) | DE69427800T2 (https=) |
| DK (1) | DK0652005T3 (https=) |
| ES (1) | ES2157957T3 (https=) |
| GR (1) | GR3036971T3 (https=) |
| HU (1) | HUT71235A (https=) |
| IL (1) | IL111284A (https=) |
| NO (1) | NO311242B1 (https=) |
| NZ (1) | NZ264677A (https=) |
| PH (1) | PH31261A (https=) |
| PT (1) | PT652005E (https=) |
| RU (1) | RU2157203C2 (https=) |
| SG (1) | SG43319A1 (https=) |
| SI (1) | SI0652005T1 (https=) |
| TW (1) | TW296382B (https=) |
| UA (1) | UA26930C2 (https=) |
| ZA (1) | ZA948029B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
| USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5847007A (en) | 1993-05-13 | 1998-12-08 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| ZA956988B (en) * | 1994-08-22 | 1997-02-21 | Lilly Co Eli | Methods of inhibiting primary endometrial hyperplasia. |
| US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
| US5554600A (en) * | 1995-01-20 | 1996-09-10 | Eli Lilly And Company | Methods for inhibiting endometriosis |
| DE69600709T2 (de) * | 1995-06-07 | 1999-03-18 | Eli Lilly And Co., Indianapolis, Ind. | Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen |
| KR970002795A (ko) | 1995-10-30 | 1997-01-28 | 모리 하루오 | 네비게이션(navigation)장치 |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| CA2214072C (en) * | 1996-08-29 | 2006-11-14 | Eli Lilly And Company | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| EP1133996A4 (en) * | 1998-11-26 | 2003-04-02 | Teikoku Hormone Mfg Co Ltd | MEDICAL COMPOSITIONS FOR PERIODIC ADMINISTRATION |
| CN1250563C (zh) | 1999-05-04 | 2006-04-12 | 斯特拉坎有限公司 | 雄激素糖苷及其产生雄性征的活性 |
| WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| JP2004531559A (ja) * | 2001-05-22 | 2004-10-14 | イーライ・リリー・アンド・カンパニー | エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体 |
| EP1395563B1 (en) * | 2001-05-22 | 2006-03-29 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
| RU2005101635A (ru) * | 2002-06-25 | 2005-08-10 | Уайт (Us) | Применение производных тиооксиндола в терапии гормонозависимых состояний |
| US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
| EA026675B1 (ru) | 2010-06-16 | 2017-05-31 | Эндорешерш, Инк. | Способы лечения или предотвращения эстрогензависимых заболеваний |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| SE500453C2 (sv) * | 1991-10-07 | 1994-06-27 | Karobio Ab | Ett in vitro förfarande för utvärdering av en substans effekter |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-10-15 US US08/138,643 patent/US5461065A/en not_active Expired - Lifetime
-
1994
- 1994-10-12 UA UA94105917A patent/UA26930C2/uk unknown
- 1994-10-13 TW TW083109467A patent/TW296382B/zh active
- 1994-10-13 KR KR1019940026164A patent/KR950010893A/ko not_active Ceased
- 1994-10-13 AT AT94307528T patent/ATE203404T1/de not_active IP Right Cessation
- 1994-10-13 ZA ZA948029A patent/ZA948029B/xx unknown
- 1994-10-13 SI SI9430388T patent/SI0652005T1/xx unknown
- 1994-10-13 IL IL11128494A patent/IL111284A/xx not_active IP Right Cessation
- 1994-10-13 CA CA002118092A patent/CA2118092A1/en not_active Abandoned
- 1994-10-13 NO NO19943879A patent/NO311242B1/no not_active IP Right Cessation
- 1994-10-13 EP EP94307528A patent/EP0652005B1/en not_active Expired - Lifetime
- 1994-10-13 DE DE69427800T patent/DE69427800T2/de not_active Expired - Fee Related
- 1994-10-13 ES ES94307528T patent/ES2157957T3/es not_active Expired - Lifetime
- 1994-10-13 DK DK94307528T patent/DK0652005T3/da active
- 1994-10-13 PH PH49186A patent/PH31261A/en unknown
- 1994-10-13 AU AU75787/94A patent/AU677700B2/en not_active Ceased
- 1994-10-13 HU HU9402959A patent/HUT71235A/hu unknown
- 1994-10-13 RU RU94036772/14A patent/RU2157203C2/ru active
- 1994-10-13 NZ NZ264677A patent/NZ264677A/en unknown
- 1994-10-13 CN CN94117125A patent/CN1049335C/zh not_active Expired - Fee Related
- 1994-10-13 JP JP6247764A patent/JPH07188014A/ja active Pending
- 1994-10-13 SG SG1996008246A patent/SG43319A1/en unknown
- 1994-10-13 PT PT94307528T patent/PT652005E/pt unknown
- 1994-10-13 CZ CZ19942537A patent/CZ287246B6/cs not_active IP Right Cessation
-
1995
- 1995-04-14 US US08/422,387 patent/US5693656A/en not_active Expired - Fee Related
-
2001
- 2001-10-22 GR GR20010401841T patent/GR3036971T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU94036772A (ru) | 1996-08-27 |
| SG43319A1 (en) | 1997-10-17 |
| JPH07188014A (ja) | 1995-07-25 |
| NO943879L (no) | 1995-04-18 |
| RU2157203C2 (ru) | 2000-10-10 |
| CZ253794A3 (en) | 1995-05-17 |
| ATE203404T1 (de) | 2001-08-15 |
| EP0652005A1 (en) | 1995-05-10 |
| ES2157957T3 (es) | 2001-09-01 |
| US5693656A (en) | 1997-12-02 |
| CA2118092A1 (en) | 1995-04-16 |
| NO311242B1 (no) | 2001-11-05 |
| SI0652005T1 (en) | 2001-12-31 |
| EP0652005B1 (en) | 2001-07-25 |
| PH31261A (en) | 1998-06-18 |
| PT652005E (pt) | 2001-11-30 |
| NO943879D0 (no) | 1994-10-13 |
| HU9402959D0 (en) | 1995-02-28 |
| US5461065A (en) | 1995-10-24 |
| DE69427800T2 (de) | 2001-12-06 |
| AU677700B2 (en) | 1997-05-01 |
| DK0652005T3 (da) | 2001-09-24 |
| GR3036971T3 (en) | 2002-01-31 |
| HUT71235A (en) | 1995-11-28 |
| UA26930C2 (uk) | 1999-12-29 |
| IL111284A (en) | 2000-02-29 |
| CN1049335C (zh) | 2000-02-16 |
| CN1107043A (zh) | 1995-08-23 |
| DE69427800D1 (de) | 2001-08-30 |
| IL111284A0 (en) | 1994-12-29 |
| ZA948029B (en) | 1996-04-15 |
| NZ264677A (en) | 1997-07-27 |
| AU7578794A (en) | 1995-05-04 |
| CZ287246B6 (en) | 2000-10-11 |
| TW296382B (https=) | 1997-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950010893A (ko) | 자궁내막증 억제 방법 | |
| KR950016732A (ko) | 피부 및 질의 위축 억제방법 | |
| KR950010890A (ko) | 폐경기 증후군의 치료방법 | |
| KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
| KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
| KR950016745A (ko) | 생리증상의 치료방법 및 이를 위한 조성물 | |
| KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
| KR950016744A (ko) | 트롬빈을 저해하는 방법 | |
| KR950016738A (ko) | 알쯔하이머 질병의 억제 방법 | |
| KR950016746A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
| KR950016730A (ko) | 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 | |
| KR950016731A (ko) | 지루 및 좌창의 억제 방법 | |
| KR950010888A (ko) | 평활근세포 증식 및 재발협착증을 억제하는 방법 | |
| KR950016726A (ko) | 기능부전성 자궁 출혈을 억제하는 방법 | |
| KR970706818A (ko) | 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) | |
| KR950010887A (ko) | 연골 퇴화 억제 방법 | |
| KR950010889A (ko) | 혈관형성 및 혈관형성성 질병을 억제하는 방법 | |
| KR950016737A (ko) | 생리전 증후군/후기 황체 시기 불쾌성 질환 증상의 억제 방법 | |
| KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
| KR950016724A (ko) | 폐경기 후 여성의 리비도를 증가시키는 방법 | |
| KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
| KR950016742A (ko) | 폐경후 여성의 씨엔에스 질환을 억제하는 방법 | |
| KR950016735A (ko) | 터너 증후군의 억제 방법 | |
| KR950016729A (ko) | 유방 질환의 억제 방법 | |
| KR960007592A (ko) | 신규한 피롤로카바졸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19941013 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19991012 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19941013 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20011123 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20020330 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20011123 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |